Real-world evidence (RWE) is becoming increasingly important in the context of health technology assessment (HTA), which is the process of evaluating the clinical and economic impact of healthcare interventions. HTA is used to inform decisions about which treatments, technologies, and interventions should be funded and made available to patients.

RWE can play an important role in HTA by providing additional data on the safety, effectiveness, and cost-effectiveness of healthcare interventions, beyond what is typically available from clinical trials. RWE can be generated from a variety of sources, including electronic health records, administrative claims data, patient registries, and other real-world data sources.

RWE can be used to supplement or replace data from clinical trials, particularly in situations where the clinical trial data is limited or may not fully reflect real-world conditions. For example, RWE can provide information on how interventions work in different patient populations, including those with comorbidities or other conditions that may not have been included in clinical trials.

In addition, RWE can provide valuable information on the long-term effectiveness and safety of interventions, as well as their impact on patient quality of life and other patient-centered outcomes. This information can be particularly important in assessing the value of interventions over the long term and in different patient populations.

Overall, RWE can play an important role in improving the quality and accuracy of HTA, by providing additional data and insights that can help to inform decisions about which healthcare interventions should be funded and made available to patients.